Background
Calcitonin was identified in the early 1960s as a circulating factor from thyroid parafollicular (C) cells that opposes parathyroid hormone's hypercalcemic action. Salmon calcitonin was developed for pharmaceutical use because it is substantially more potent and longer-acting in humans than the endogenous human sequence. From the 1970s onward, injectable and later intranasal salmon calcitonin became available for Paget disease, acute hypercalcemia, and vertebral fracture pain. By the 1990s it was also used for osteoporosis, but fracture-prevention evidence never matched that of bisphosphonates. In 2013, the European Medicines Agency restricted long-term salmon calcitonin use after meta-analyses suggested a small increased cancer risk with chronic exposure, shifting its role firmly toward short-term indications.
Evidence snapshot
Clinical evidence supports calcitonin's short-term effectiveness for lowering serum calcium in acute hypercalcemia and for reducing biochemical markers of bone turnover. The analgesic benefit for acute vertebral fracture pain is supported by multiple randomized controlled trials, though effect sizes are modest and benefits are primarily limited to the first few weeks of treatment.
For chronic fracture risk reduction in osteoporosis, evidence is weak and inconsistent. Systematic reviews and regulatory assessments have found limited fracture-prevention benefit relative to bisphosphonates or denosumab. Regulatory agencies identified a small but uncertain increased risk of malignancy with long-term salmon calcitonin use, prompting label restrictions and withdrawal of the chronic osteoporosis indication in several jurisdictions.
Calcitonin remains useful in selected short-term situations: emergency management of hypercalcemia, symptomatic Paget disease, analgesia in the acute phase after vertebral fracture, and as a serum tumor marker for medullary thyroid carcinoma. It is not a first-line or long-term option for osteoporosis prevention.
Bioavailability and formulations
Calcitonin is a peptide and is not bioavailable when taken orally in conventional form. Available pharmaceutical formulations include intranasal sprays (salmon calcitonin 200 IU per actuation) and parenteral injections (100 IU intramuscular or subcutaneous). Intranasal bioavailability is substantially lower than parenteral routes, which is why intranasal doses are expressed at higher IU values. Oral peptide delivery technologies and sustained-release formulations have been investigated but are not established in routine clinical practice.
Populations studied and efficacy
Clinical trials have primarily enrolled postmenopausal women with osteoporosis, patients with Paget disease, and individuals with acute vertebral compression fractures. Evidence consistently supports short-term reductions in bone resorption markers and modest analgesia after vertebral fracture. Large, consistent fracture-prevention benefits — comparable to those demonstrated for bisphosphonates or denosumab — have not been demonstrated for calcitonin, and regulatory agencies concluded the benefit-risk balance does not support chronic osteoporosis use.
Long-term safety and regulatory guidance
Meta-analyses and regulatory reviews, most notably the 2013 EMA assessment, identified a small but statistically uncertain increased incidence of malignancies (predominantly prostate and digestive cancers) in patients using salmon calcitonin long-term. The EMA recommended restricting calcitonin to short-term use and withdrawing or restricting the chronic osteoporosis indication. Clinicians should weigh short-term symptomatic benefits against this unresolved safety signal and prefer established first-line agents for fracture prevention.
Diagnostic uses
Serum calcitonin is an established biomarker for medullary thyroid carcinoma (MTC) detection and post-treatment surveillance. Baseline measurement and, where available, stimulated calcitonin testing (using intravenous calcium infusion) are used in endocrinology practice. Elevated calcitonin from non-thyroidal causes — chronic kidney disease, other neuroendocrine tumors, proton pump inhibitor use, and hypercalcemia itself — should be considered in interpretation. Thresholds and protocols are assay-dependent and should follow current endocrine society guidelines.
Compound variations
Salmon calcitonin
The most commonly used pharmaceutical form; substantially more potent and longer-acting in humans than human calcitonin. Available as intranasal spray (Miacalcin, Fortical) and injectable formulations.
Common use case
Short-term treatment of acute hypercalcemia, vertebral fracture pain, and active Paget disease.
Dosage note
Intranasal: 200 IU once daily, alternating nostrils. Injectable: 100 IU SC or IM every 24–48 hours for acute indications. Duration should be limited per regulatory guidance.
Synthetic human calcitonin
Matches the endogenous 32-amino-acid sequence but is less potent than salmon calcitonin; less commonly used in clinical practice.
Common use case
Research applications and situations where a human-sequence product is clinically preferred; rarely used in routine practice.
Dosage note
Formulation-dependent; human calcitonin products have limited commercial availability in most markets.
Elcatonin (eel calcitonin)
An eel-derived calcitonin analog with structural modifications that confer resistance to enzymatic degradation; used in Japan and some other countries for bone pain and osteoporosis.
Common use case
Short-term pain relief for vertebral fractures and bone disorders in regions where the product is approved and available.
Dosage note
Dosing varies by country and product labeling; follow local prescribing information.
Synthetic calcitonin analogues and novel delivery systems
Investigational analogues and alternative delivery technologies — including oral peptide formulations and sustained-release injectables — are being studied for improved pharmacokinetics or safety profiles.
Common use case
Research and clinical trials; not available in routine clinical practice.
Dosage note
Dosing and safety are protocol-specific; not applicable outside investigational settings.
Dosage and best practices
Dosage principles
- Intranasal salmon calcitonin: 200 IU once daily (one spray; alternating nostrils daily). Clinical use is typically limited to weeks for pain management after vertebral fracture.
- Injectable salmon calcitonin: 100 IU subcutaneously or intramuscularly every 24–48 hours for hypercalcemia or Paget disease; frequency is adjusted based on clinical response and tolerability.
- Analgesic use after vertebral fracture: trials used intranasal 200 IU/day or 100 IU parenteral for 2–6 weeks and demonstrated short-term pain reduction. Prolonged courses are not recommended given uncertain long-term benefit and safety signals.
- Diagnostic use (medullary thyroid carcinoma): serum calcitonin measurement and stimulated testing (calcium or pentagastrin stimulation where available) follow laboratory- and assay-specific reference ranges. Interpretation and protocol should follow endocrinology guidance.
Best practices
- Reserve calcitonin for short-term indications (acute hypercalcemia, acute vertebral fracture pain, active Paget disease) and under specialist guidance; reassess need at regular intervals.
- Monitor serum calcium and renal function during treatment. Biochemical markers of bone turnover typically fall within days to weeks of initiating therapy.
- For intranasal formulations: use alternate-nostril technique, prime the pump before first use, and avoid inhaling through the nose during administration. Injectable forms are given SC or IM per product instructions.
- In patients with fish or salmon allergy, avoid salmon-derived calcitonin; discuss alternatives with the prescribing clinician.
- For osteoporosis, evaluate whether a bisphosphonate, denosumab, or other approved antiresorptive is more appropriate before selecting calcitonin.
Literature and references
European Medicines Agency recommends restrictions on calcitonin-containing medicines
European Medicines Agency (EMA) • 2013
The EMA recommended restricting calcitonin-containing medicines for men and postmenopausal women because of a small increased risk of malignancies with long-term use, advising limitation to short-term treatment of acute pain due to osteoporotic vertebral fractures.
Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA • 2005
Systematic review of RCTs examining calcitonin for acute vertebral fracture pain; found modest short-term analgesic benefit, primarily in the first weeks after fracture onset.
Salmon calcitonin use and associated cancer risk
The Annals of pharmacotherapy • 2013
Review evaluating the strength of evidence for a possible association between salmon calcitonin use and cancer incidence, following regulatory analyses of randomized trial data.
Common questions
Is calcitonin effective for long-term osteoporosis prevention?
No. Long-term fracture-prevention data are weak and inconsistent, and calcitonin does not match the efficacy of bisphosphonates or denosumab. Combined with regulatory concerns about prolonged use, it is not recommended as first-line or long-term osteoporosis therapy.
Can I use salmon calcitonin if I am allergic to fish?
Caution is warranted. Salmon-derived calcitonin carries a risk of allergic cross-reactivity in people with fish or salmon allergy. Discuss your allergy history with your clinician; alternatives include synthetic human calcitonin or non-calcitonin osteoporosis therapies.
How quickly does calcitonin lower high blood calcium?
Serum calcium can begin falling within hours of parenteral calcitonin administration, making it useful as a temporizing measure in acute hypercalcemia. The effect is modest and transient; concurrent investigation and treatment of the underlying cause are essential.
What monitoring is needed during calcitonin treatment?
Monitor serum calcium and renal function during the course of treatment, and watch for common adverse effects (nausea, flushing, nasal irritation). For any course extending beyond a few weeks, reassess the benefit-risk balance given regulatory cautions about prolonged use.
Can calcitonin be used alongside other osteoporosis drugs?
Sequential or short-term adjunctive use is described in the literature, but combining calcitonin with other potent antiresorptives (bisphosphonates, denosumab) increases the risk of hypocalcemia. Any combination should be individualized and monitored with your clinician.